Analysts have also raised estimates for Abbott Laboratories and Las Vegas Sands. Over 64% of analysts cover Abbott with a buy rating, and its stock has risen about 17% over the past three months despite modest sector performance. Barclays initiated coverage of Abbott at an overweight rating, projecting accelerated revenue growth as nutrition and diagnostics businesses recover and medical device sales continue to expand, with 10%–11% growth expected from 2027 to 2029. Las Vegas Sands, owner of Marina Bay Sands, has seen its earnings estimate surge 360% to 74 cents per share over six months, even as its share price declined in recent months. Long‑term growth in the Asia‑Pacific gaming market, bolstered by events such as the Singapore Grand Prix, may support further upside.

Source link

Exit mobile version